References in periodicals archive ?
Hydroxycarbamide or hydroxyurea is a chemotherapy drug used to treat many diseases, including sickle cell disease, melanoma, ovariantumor, squamous cell carcinoma of the head and neck, renal carcinoma, chronic myelogenous leukemia, prostate carcinoma and carcinoma of the uterine cervix [22] chronic myeloid leukemia, cervical cancer and polycythemia vera.
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.
Hydroxycarbamide (HC) is recommended as the first-line treatment modality for the management of patients within the spectrum of certain myeloproliferative neoplasms, as polycythemia vera and essential thrombocytosis (ET) [1, 2].
Dossou-Yovo et al., "Hydroxycarbamide stimulates the production of proinflammatory cytokines by endothelial cells: relevance to sickle cell disease," Pharmacogenetics and Genomics, vol.
Schultz et al., "Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH) : a multicentre, open-label, phase 3, non-inferiority trial," The Lancet, vol.
Miller et al., "Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)," The Lancet, vol.
Hydroxyurea or hydroxycarbamide is a cytotoxic agent frequently used to treat SCA to reduce the number and frequency of pain episodes, vasoocclusive crises, episodes of acute chest syndrome, and hospitalizations by raising fetal hemoglobin (HbF) levels [60, 61].